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the range observed in the general population. 4 Thus far, data from more than 2000 propranolol-treated infants in clinical studies and a compassionate-use program in France have been reassuring, but we agree that there is a need for large studies assessing longer-term outcomes.
To date, propranolol is by far the best-studied beta-blocker in infants. We believe that any assessment of its benefits and potential risks should take into account that the efficacy and safety profiles of alternative drugs used for this condition are not as well documented. Christine Léauté-Labrèze, M.D. The Authors Reply: We agree with Saver that the ongoing use of routine preoperative testing in patients undergoing cataract surgery may result from institutional requirements rather than the practice patterns of individual providers. Other authors have reported that physicians order testing because of tradition, medicolegal concerns, or the belief that another physician expects testing before cataract surgery. 1,2 Although it may be difficult to change institutional dogma and entrenched practice patterns, we believe that physicians should feel empowered to question and update policies and protocols that have not kept up with current evidence-based recommendations in order to provide better and highervalue care to their patients. In 2000, the American Academy of Ophthalmology issued a clinical statement recommending against the use of routine preoperative testing in patients undergoing cataract surgery, and the organization updated this statement in 2014. 3 For low-risk elective ambulatory procedures such as cataract surgery, patients in their usual state of health should be allowed to proceed to the operating room without any further workup. 3-5
Since publication of their article, the authors report no further potential conflict of interest. 
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Clostridium difficile Infection
To the Editor: The review article on Clostridium difficile infection by Leffler and Lamont (April 16 issue) 1 updates previous reviews and will serve as a valuable reference. The authors address the association between acid suppression and the risk factors for C. difficile infection. We would suggest that evidence of the association of the use of proton-pump inhibitors (PPIs) with C. difficile infection is more compelling than posited. In addition to biologic plausibility, a large, prospective, observational study by Loo et al. 2 showed a strong association between PPI use and the development of infection due to C. difficile, and this association has been recognized by the Food and Drug Administration. 3 Observational studies also have shown that continuous PPI use is common in patients with C. difficile infection (in 40 to 60% of patients) and may be associated with an increased risk of recurrence. 4,5 Furthermore, approximately half of PPIs in patients with C. difficile infection are prescribed continuously without an evidence-based indication. 5 We recognize the limitations of observational studies. However, it seems reasonable to acknowledge this potential association and discontinue the unnecessary use of PPIs in patients who are at risk for a first or recurrent C. difficile infection. No potential conflict of interest relevant to this letter was reported.
